VERAXA Biotech AG (NASDAQ: VRXA) is highlighting partnering opportunities for its proprietary BiTAC-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity.
VERAXA said the findings, together with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both technologies at the BIO International Convention, scheduled for June 22-25, 2026, in San Diego.
These platforms represent a significant advancement in oncology. The BiTAC-ADC platform uses bispecific antibodies to deliver cytotoxic drugs directly to tumor cells, while BiTAC-TCE engages T cells to attack cancer cells. Both approaches aim to overcome limitations of conventional therapies, such as lack of specificity and systemic toxicity. The new data suggests improved efficacy and safety profiles, which could expand treatment options for patients with solid tumors.
The company’s strategy to seek partnerships at BIO underscores the importance of collaborative development in bringing these technologies to market. By licensing its platforms, VERAXA can accelerate clinical trials and leverage partners' expertise in manufacturing and commercialization. This could lead to faster patient access to novel therapies.
For more details, the full press release is available at https://ibn.fm/1je4A. Additional updates on VRXA can be found at http://ibn.fm/VRXA.
